Priorities

The Healthcare Biotechnology Council has priorities selected by Members for shared work throughout the year, delivered through working groups and Council meetings. Priorities include:

Medicines for Rare Diseases & Children

Encouragement is needed for investment into Research & Development for rare diseases currently suffering from lack of treatment or unmet need. EuropaBio places particular attention on working with public authorities to discuss patient access to novel, often advanced, treatments created by the research to date.

Advanced Therapeutics

Awareness raising is critical for the transformative impact of cell and gene therapies for patients and society. Healthcare systems also need adaptation to ensure that patients across the EU can fully benefit from such therapeutics.

Patient priorities

This priority underpins many EuropaBio activities. The input and views from patient organisations on scientific, regulatory and policy issues actively sought and integrated, to enable better support for EuropaBio contributions to the healthcare policy debate in the EU. The Patient BioForum is at the centre of this priority.

Digital healthcare advances

This is an increasing priority for EuropaBio, addressing how the digital revolution will affect healthcare, including improvement of the R&D for new diagnostics and treatments for illnesses.

Regulatory Efficiency

EuropaBio seeks a progressive regulatory framework for efficient uptake of new healthcare biotechnologies in the EU. We actively engage in the implementation of the European Health Union, the EU Pharmaceutical Strategy, as well as in the EMA and HMA regulatory strategies with a view to support speed, innovation and EU competitiveness.

Biosimilars & Public Procurement

The final priority for the Healthcare Council, sees EuropaBio advocating for a high standard of clinical evidence before issuing any new medicine to a patient, and supporting public procurement as a means of improving patient access to innovative medicines.